1. Home
  2. BIVI vs MBAI Comparison

BIVI vs MBAI Comparison

Compare BIVI & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.75

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.41

Market Cap

10.3M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
BIVI
MBAI
Founded
2013
2004
Country
United States
Israel
Employees
N/A
85
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
10.3M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
BIVI
MBAI
Price
$1.75
$1.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
100.2K
63.0K
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$1.29
52 Week High
$9.09
$3.92

Technical Indicators

Market Signals
Indicator
BIVI
MBAI
Relative Strength Index (RSI) 60.44 41.42
Support Level $1.17 $1.30
Resistance Level $1.78 $1.83
Average True Range (ATR) 0.15 0.11
MACD 0.02 -0.02
Stochastic Oscillator 76.47 20.00

Price Performance

Historical Comparison
BIVI
MBAI

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: